Natural and Medical Sciences Research Center, University of Nizwa, P.O Box 33, Postal Code 616, Birkat Al Mauz, Nizwa, Sultanate of Oman; Department of Zoology, Abdul Wali Khan University Mardan, Mardan-23200, Pakistan.
Natural and Medical Sciences Research Center, University of Nizwa, P.O Box 33, Postal Code 616, Birkat Al Mauz, Nizwa, Sultanate of Oman; Department of Biotechnology and Genetic Engineering, Hazara University Mansehra, Dhodial 21120, Pakistan.
Int J Biol Macromol. 2023 Jun 1;239:124320. doi: 10.1016/j.ijbiomac.2023.124320. Epub 2023 Mar 31.
Coxsackievirus B3 (CVB3) is a viral pathogen of various human disorders with no effective preventative interventions. Herein, we aimed to design a chimeric vaccine construct for CVB3 using reverse vaccinology and immunoinformatics approaches by screening the whole viral polyprotein sequence. Firstly, screening and mapping of viral polyprotein to predict 21 immunodominant epitopes (B-cell, CD8+ and CD4+ T-cell epitopes), fused with an adjuvant (Resuscitation-promoting factor), appropriate linkers, HIV-TAT peptide, Pan DR epitope, and 6His-tag to assemble a multi-epitope vaccine construct. The chimeric construct is predicted as probable antigen, non-allergen, stable, possess encouraging physicochemical features, and indicates a broader population coverage (98 %). The tertiary structure of the constructed vaccine was predicted and refined, and its interaction with the Toll-like receptor 4 (TLR4) was investigated through molecular docking and dynamics simulation. Computational cloning of the construct was carried out in pET28a (+) plasmid to guarantee the higher expression of the vaccine protein. Lastly, in silico immune simulation foreseen that humoral and cellular immune responses would be elicited in response to the administration of such a potent chimeric construct. Thus, the design constructed could vaccinate against CVB3 infection and various CVB serotypes. However, further in vitro/in vivo research must assess its safety and effectiveness.
柯萨奇病毒 B3(CVB3)是一种可引起多种人类疾病的病毒病原体,目前尚无有效的预防干预措施。在此,我们旨在通过筛选整个病毒多蛋白序列,使用反向疫苗学和免疫信息学方法为 CVB3 设计嵌合疫苗构建体。首先,对病毒多蛋白进行筛选和映射,以预测 21 个免疫显性表位(B 细胞、CD8+和 CD4+T 细胞表位),与佐剂(复苏促进因子)、合适的接头、HIV-TAT 肽、Pan DR 表位和 6His 标签融合,组装成多表位疫苗构建体。该嵌合构建体被预测为可能的抗原,非过敏原,稳定,具有令人鼓舞的物理化学特性,并表明更广泛的人群覆盖率(98%)。构建疫苗的三级结构进行了预测和优化,并通过分子对接和动力学模拟研究了其与 Toll 样受体 4(TLR4)的相互作用。该构建体的计算克隆在 pET28a(+)质粒中进行,以保证疫苗蛋白的高表达。最后,通过计算机模拟免疫预测,针对这种有效的嵌合构建体给药,会引发体液和细胞免疫反应。因此,该设计构建体可以预防 CVB3 感染和各种 CVB 血清型。然而,还需要进一步的体外/体内研究来评估其安全性和有效性。